Sponsored by
xCures is running an expanded access program of this drug for any type of cancer that has MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies. Low grade gliomas have a high chance of having this mutation. Glioblastomas, Pancreatic Cancer, Colon cancer, Ovarian and more types of cancers also sometimes get this mutation. Check your pathology report for it.